Enanta Pharmaceuticals, Inc
ENTA Real Time Price USDRecent trades of ENTA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ENTA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Nov 14, 2023 Issue: Health Issues
Estimated quarterly lobbying spending
ENTA Revenue by Segment or Geography
New patents grants
-
Patent Title: Combination pharmaceutical agents as rsv inhibitors Apr. 08, 2025
-
Patent Title: Functionalized heterocycles as antiviral agents Apr. 01, 2025
-
Patent Title: Antiviral compounds Dec. 10, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents Nov. 19, 2024
-
Patent Title: Heterocyclic antiviral agents Nov. 19, 2024
-
Patent Title: Hepatitis b antiviral agents Aug. 06, 2024
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Jun. 25, 2024
-
Patent Title: Hepatitis b antiviral agents Jun. 18, 2024
-
Patent Title: Antiviral heterocyclic compounds Jun. 11, 2024
-
Patent Title: Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid Jun. 11, 2024
-
Patent Title: Saturated spirocyclics as antiviral agents May. 28, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents May. 07, 2024
-
Patent Title: Macrocyclic antiviral agents Apr. 30, 2024
-
Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Apr. 16, 2024
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Apr. 09, 2024
-
Patent Title: Antiviral heterocyclic compounds Apr. 02, 2024
-
Patent Title: Heterocyclic compounds as anti-viral agents Apr. 02, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents Mar. 05, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents Feb. 27, 2024
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Feb. 27, 2024
-
Patent Title: Functionalized heterocycles as antiviral agents Feb. 06, 2024
-
Patent Title: Alkyne-containing antiviral agents Jan. 02, 2024
-
Patent Title: Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Dec. 05, 2023
-
Patent Title: Hepatitis b antiviral agents Sep. 19, 2023
-
Patent Title: Substituted heterocycles as antiviral agents Aug. 29, 2023
-
Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Aug. 08, 2023
-
Patent Title: Hepatitis b antiviral agents Mar. 07, 2023
-
Patent Title: Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof Feb. 14, 2023
-
Patent Title: Antiviral heterocyclic compounds Feb. 07, 2023
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Jan. 24, 2023
-
Patent Title: Isoxazole derivatives as fxr agonists and methods of use thereof Jan. 17, 2023
-
Patent Title: Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors Dec. 27, 2022
-
Patent Title: Antiviral heterocyclic compounds Nov. 22, 2022
-
Patent Title: Substituted pyrrolo[1,2-c]pyrimidines as hepatitis b antiviral agents Oct. 18, 2022
-
Patent Title: Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors Oct. 11, 2022
-
Patent Title: Heterocyclic compounds as anti-viral agents Aug. 23, 2022
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Jul. 19, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents Jul. 12, 2022
-
Patent Title: Functionalized heterocycles as antiviral agents Jul. 05, 2022
-
Patent Title: Functionalized peptides as antiviral agents Jun. 14, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents Jun. 07, 2022
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof May. 31, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents May. 24, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents May. 10, 2022
-
Patent Title: Macrocyclic spiropyrrolidine derived antiviral agents May. 03, 2022
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Feb. 22, 2022
-
Patent Title: Hepatitis b antiviral agents Feb. 01, 2022
-
Patent Title: Functionalized heterocycles as antiviral agents Feb. 01, 2022
-
Patent Title: Functionalized heterocycles as antiviral agents Dec. 14, 2021
-
Patent Title: Heterocyclic compounds as rsv inhibitors Nov. 23, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ENTA
Recent picks made for ENTA stock on CNBC
ETFs with the largest estimated holdings in ENTA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ENTA stock a Buy, Sell, or Hold?
- What is the price target for $ENTA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ENTA stock?
- Who owns the most shares of $ENTA stock?
- What funds own $ENTA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ENTA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.